Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Express Scripts
Johnson and Johnson
Harvard Business School

Last Updated: February 22, 2020

DrugPatentWatch Database Preview

Drugs in Development Information for AGN-201904

Email this page to a colleague

See Plans and Pricing

« Back to Dashboard

What is the development status for investigational drug AGN-201904?

AGN-201904 is an investigational drug.

There have been 47 clinical trials for AGN-201904. The most recent clinical trial was a Phase 3 trial, which was initiated on May 1st 2014.

The most common disease conditions in clinical trials are Rosacea, Keratoconjunctivitis Sicca, and Ocular Hypertension. The leading clinical trial sponsors are Allergan, Editas Medicine, Inc., and Naurex, Inc, an affiliate of Allergan plc.

There are two US patents protecting this investigational drug and forty-three international patents.

Recent Clinical Trials for AGN-201904
A Study of the Drugs AGN-242428 and AGN-231868 in Participants With Dry Eye DiseaseAllerganPhase 1/Phase 2
AGN-151586 Dose-Ranging Study for Treatment of Glabellar LinesAllerganPhase 2
Single Ascending Dose Study in Participants With LCA10Editas Medicine, Inc.Phase 1/Phase 2

See all AGN-201904 clinical trials

Clinical Trial Summary for AGN-201904

Top disease conditions for AGN-201904
Top clinical trial sponsors for AGN-201904

See all AGN-201904 clinical trials

US Patents for AGN-201904

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
AGN-201904   Start Trial Prodrugs of proton pump inhibitors Winston Pharmaceuticals, Inc. (Newport Beach, CA) The United States of America as represented by the Department of Veteran Affairs (Washington, DC) N/A (Oakland, CA) The Reagents of the University of California (N/A)   Start Trial
AGN-201904   Start Trial Process for preparing isomerically pure prodrugs of proton pump inhibitors Allergan, Inc. (Irvine, CA)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.